Oramed's RoyaltyVest signs exclusive Rest of World license for Scilex lidocaine products ZTlido/SP-103

ORAMED PHARMACEUTICALS INC.

RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.
Revenue share: RoyaltyVest and Scilex Pharma each receive 50% of Net Revenue, paid quarterly by RoyaltyVest.
Licensee must commit $200,000 annually (or in-kind) and obtain regulatory approval in at least one Major Market Country within 18 months of effective date.
Scilex Holding Company guaranteed Scilex Pharma's obligations under the license via a parent guarantee; guarantee terminates upon a change of control.
Oramed transferred 50% of RoyaltyVest shares to Oramed; Oramed controls half of RoyaltyVest's board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.